In consequence, despite the JAK/STAT pathway is the second most frequently deregulated signaling pathway in precursor T-cell neoplasms, there is no specific treatment for T-ALL/LBL patients with JAK/STAT pathway mutations7. Here, SOAT1 is linked to T-cell and NK-cell neoplasm.